BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zheng LL, Tao CC, Tao ZG, Zhang K, Wu AK, Wu JX, Rong WQ. Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1136-1148 [PMID: 34754383 DOI: 10.4240/wjgs.v13.i10.1136]
URL: https://www.wjgnet.com/1948-9366/full/v13/i10/1136.htm
Number Citing Articles
Bahareh Farasati Far, Dorsa Rabie, Parisa Hemati, Parastoo Fooladpanjeh, Neda Faal Hamedanchi, Nima Broomand Lomer, Arian Karimi Rouzbahani, Mohammad Reza Naimi-Jamal. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and ImmunotherapyLivers 2023; 3(1): 121 doi: 10.3390/livers3010011
Pengfei Chen, Yingjing Li, Pengkun Wei, Lirui Liang, Baozhu Li, Yuhao Cao, Xinwei Han, Yanling Wang, Xuhua Duan, Huijie Jia, Tieuso Zhao, Jianzhuang Ren. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinomaInternational Immunopharmacology 2022; 111: 109127 doi: 10.1016/j.intimp.2022.109127